The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 09, 2018

Filed:

Oct. 29, 2008
Applicants:

Michal Aharonowiz, Modiin, IL;

Ofira Einstein, Modiin, IL;

Benjamin Reubinoff, Doar Na Haela, IL;

Tamir Ben-hur, Jerusalem, IL;

Inventors:

Michal Aharonowiz, Modiin, IL;

Ofira Einstein, Modiin, IL;

Benjamin Reubinoff, Doar Na Haela, IL;

Tamir Ben-Hur, Jerusalem, IL;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 5/0797 (2010.01); A61K 35/30 (2015.01); A61K 35/12 (2015.01);
U.S. Cl.
CPC ...
C12N 5/0623 (2013.01); A61K 35/30 (2013.01); A61K 2035/122 (2013.01); C12N 2501/105 (2013.01); C12N 2501/11 (2013.01); C12N 2501/115 (2013.01); C12N 2501/13 (2013.01); C12N 2501/135 (2013.01); C12N 2501/385 (2013.01); C12N 2501/395 (2013.01); C12N 2501/41 (2013.01); C12N 2501/70 (2013.01); C12N 2506/02 (2013.01);
Abstract

The present invention concerns the use of a population of cells comprising: (a) neural precursor cells committed to an oligodendroglial fate; (b) uncommitted neural precursor cells (c) differentiated oligodendrocytes; or (d) a combination of any one of (a) to (c) for the treatment of CNS autoimmune diseases, or for the preparation of a pharmaceutical composition for treating CNS autoimmune diseases, the population of cells being derived from human pluripotent stem cells. The invention also provides methods for obtaining such populations of cells, namely, neural precursor cells committed to an oligodendroglial fate as well as differentiated oligodendrocytes which then can be used in the treatment of CNS autoimmune diseases. A preferred autoimmune disease in the context of the present invention is multiple sclerosis where the population of cells is administered to the CNS for local treatment of the disease.


Find Patent Forward Citations

Loading…